Compare Regeneron Pharmaceuticals Inc (REGN) vs Sea Limited (SE) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

SE trades at $113.33, up 1.11% today, with a bullish technical outlook as the price sits above key support at $111. Revenue grew to $22.94B in 2025, with net income reaching $1.58B, and analysts project a consensus price target of $143.67. Recent insider sales by executives have occurred, but the company maintains strong cash flow from operations of $5.02B.

The outlook is positive given robust revenue growth and improving profitability, but risks include competitive pressures in e-commerce and potential volatility from insider selling. Wall Street sentiment remains bullish with 70% buy ratings, supporting upside potential if earnings continue to beat expectations.